Final analysis of phase 3 ANDROMEDA (388 patients with newly diagnosed AL amyloidosis): daratumumab plus VCd vs VCd raised haematological complete response (59.5% vs 19.2%) and improved overall survival (HR 0.62) at median 61.4 months.
RCTn = 388
Kastritis et al. Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis